Tagged with Research,

Denmark Marianne Pilgaard discusses the evolution of Denmark’s clinical trial landscape, the continued top-tier status of the country in trial activity per capita, and the nation’s commitment to digital innovation and patient-centric research. Pilgaard covers the impact of healthcare reform, regulatory harmonisation, decentralised trials, and the prospects for advanced therapies and…

USA Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government has pulled the plug on the HIV vaccine programme run by the US National Institute of Health (NIH) –the world’s…

Research Andreas Lysandropoulos, Senior Vice President and Global Therapeutic Area Head for Neuroscience at Parexel, shares his insights on the evolving landscape of clinical development for neurological conditions. In this interview, he highlights the importance of localised patient engagement, the role of advocacy in building urgency around diseases like Alzheimer’s, and…

Saudi Arabia Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSHRC), discusses the hospital’s transformation into a world-class medical and research institution, aligning with Saudi Arabia’s Vision 2030. He shares insights into KFSHRC’s pioneering efforts in oncology, transplantation, genetics, and cutting-edge medical technology, as well as its role…

Mexico Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an economic outflow of over 240 million dollars per annum in the process. Indeed, most of the major biopharma multinationals now…

Puerto Rico Dr. Eduardo Nicolau shares his journey from being a professor of chemistry to becoming Executive Director of the MSRC in 2021. His leadership focuses on financial stability, creating a biotech incubator, and establishing key partnerships with the industry, including a significant collaboration with the biotechnology company CytoImmune Therapeutics for cancer…

Puerto Rico Lucy Crespo, CEO of the Puerto Rico Science Technology and Research Trust, highlights significant recent advancements in establishing Puerto Rico as a global innovation hub, including the recent designation of Puerto Rico as one of the US Economic Development Administration’s technology hubs (Tech Hubs) and the opening of the island’s…

Puerto Rico Ivan Lugo-Montes emphasizes the Puerto Rico Bioscience Cluster (INDUNIV)’s instrumental role in advancing the island’s biosciences industry for over 60 years. Driven by innovation, workforce development, and global competitiveness, the Cluster has achieved significant milestones in advanced manufacturing, pharmaceutical cold chain logistics certification, business promotion, and international partnerships. Key initiatives…

Mexico Arturo Rodriguez, CEO of Infinite Clinical Research, discusses the current state of clinical trials in Mexico and highlights the country’s unique advantages, such as a diverse population with experienced medical professionals and top-notch medical facilities. He addresses the challenges of streamlining regulatory processes and the need for improvements to attract…

Global Contract research organisations (CROs) have proven to be increasingly vital partners for the global biopharmaceutical industry guaranteeing efficient and compliant clinical trials that help to advance their candidates towards regulatory approvals. CROs have also demonstrated their ability to adapt to the industry’s changing needs by enlarging their geographical reach and…

Switzerland Jürg Utzinger, Director of the Swiss Tropical and Public Health Institute (Swiss TPH), addresses global health challenges, the significance of partnerships and the impact of new technologies on health outcomes. He states, “Our mission is to make the world a healthier place, focusing on topics such as climate change, infectious…

Global The US National Institutes of Health (NIH) is the largest public investor in HIV/AIDS research globally. This means that, as Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy & Infectious Diseases (NIAID) Dr Carl Dieffenbach oversees a global HIV/AIDS research portfolio of more than…